<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-6094</journal-id>
<journal-title><![CDATA[Sanus]]></journal-title>
<abbrev-journal-title><![CDATA[Sanus]]></abbrev-journal-title>
<issn>2448-6094</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Sonora, División de Ciencias Biológicas y de la Salud, Departamento de enfermería]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-60942021000100205</article-id>
<article-id pub-id-type="doi">10.36789/revsanus.vi1.250</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento farmacológico en pacientes con COVID-19: una revisión integradora]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tratamento farmacológico em pacientes com COVID-19: uma revisão integrativa]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacologic treatment in patients with COVID-19: an integrative review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Melendrez-Arango]]></surname>
<given-names><![CDATA[Esthela Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durán-Aguirre]]></surname>
<given-names><![CDATA[María Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiñones-Lucero]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peralta-Peña]]></surname>
<given-names><![CDATA[Sandra Lidia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[María Rubi]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Sonora Departamento de Enfermería ]]></institution>
<addr-line><![CDATA[Hermosillo Sonora]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Sonora Departamento de Enfermería ]]></institution>
<addr-line><![CDATA[Hermosillo Sonora]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>6</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-60942021000100205&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-60942021000100205&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-60942021000100205&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción La salud hoy más que nunca ha sido vulnerada, la humanidad está sufriendo por la invasión del coronavirus SARS-CoV-2, que ha expuesto al mundo a la peor emergencia sanitaria en este siglo. La comunidad científica y los sistemas de salud global conjuntan esfuerzos en la búsqueda de un tratamiento definitivo, a la fecha se reconoce que la terapia está dirigida a mitigar los síntomas.  Objetivo Identificar las evidencias científicas sobre el tratamiento farmacológico en los pacientes con COVID-19.  Metodología Se realizó una revisión integradora de la literatura publicada de diciembre 2019 a octubre 2020, en los sistemas de información Clinical Key, Dialnet, EBSCO Host y Scopus, mediante los descriptores Coronavirus Infections, COVID-19, Drug therapy, tratamiento farmacológico. Los criterios de selección fueron artículos de investigación cuantitativa de cualquier tipo de diseño, en inglés y español disponibles a texto completo, obteniéndose una muestra de 24 artículos.  Resultados La mayoría de los estudios fueron revisiones integrativas con 66.6% y ensayos clínicos o in vitro con 12.5%. Se identificaron en la terapia farmacológica nueve medicamentos de mayor uso en COVID-19: Hidroxicloroquina/cloroquina, lopinavir/ritonavir, remdesivir, azitromicina, ivermectina, tocilizumab y dexametasona, no obstante, solo cuatro fármacos mostraron efectividad significativa según la evidencia científica.  Conclusiones remdesivir demostró mayor efectividad y seguridad en el tratamiento, tocilizumab y dexametasona mostraron resultados favorables, sin embargo, los resultados no son contundentes. Los autores señalan que aún no es posible afirmar que se dispone de tratamientos que combata la COVID-19 efectivamente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Abstrato  Introdução Hoje, mais do que nunca, a saúde humana foi comprometida; a humanidade está sofrendo com a invasão do coronavírus SARS-CoV-2, que expôs o mundo à pior emergência sanitária deste século. Embora a comunidade científica e os sistemas globais de saúde estejam unindo esforços na busca por um tratamento definitivo, até o momento é reconhecido que a terapia visa mitigar os sintomas. Identificar evidências científicas sobre o tratamento farmacológico de pacientes com COVID-19.  Objetivo Identificar evidências científicas sobre o tratamento farmacológico para pacientes com COVID-19.  Metodologia Foi realizada uma revisão integrativa da literatura publicada de dezembro de 2019 a outubro de 2020, nos seguintes sistemas de informação Clinical Key, Dialnet, EBSCO Host e Scopus utilizando os descritores Coronavirus Infections, COVID-19, Drug therapy, and pharmacological treatment. Os critérios de seleção foram artigos de pesquisa quantitativa, de qualquer tipo de delineamento, nos idiomas inglês e espanhol, disponíveis na íntegra, obtendo-se uma amostra de 24 artigos.  Resultados A maioria dos estudos foram revisões integrativas com percentual de 66,6 e ensaios clínicos ou in vitro com percentual de 12,5. Nove medicamentos de maior uso no COVID-19 foram identificados na terapia medicamentosa, ou seja, Hidroxicloroquina/Cloroquina, Lopinavir/Ritonavir, Remdesivir, Azitromicina, Ivermectina, Tocilizumabe e Dexametasona. No entanto, de acordo com as evidências científicas, apenas quatro medicamentos mostraram eficácia significativa.  Conclusões De acordo com as evidências científicas, apenas quatro medicamentos mostraram eficácia significativa. Conclusões: Remdesivir demonstrou maior eficácia e segurança durante o tratamento, e Tocilizumabe e Dexametasona apresentaram resultados favoráveis. No entanto, os resultados não são conclusivos. Os autores apontaram que até o momento não é possível concluir que existam tratamentos que combatam efetivamente o COVID-19.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction Today more than ever human health has been compromised; humanity is suffering from the invasion of the SARS-CoV-2 coronavirus, which has exposed the world to the worst health emergency in this century. Although the scientific community and global health systems are joining efforts in the search for a definitive treatment, to date it is recognized that the therapy is aimed at mitigating the symptoms.  Objective Identify scientific evidence on pharmacological treatment for patients with COVID-19.  Methodology An integrative review of literature published from December 2019 to October 2020, in the following information systems Clinical Key, Dialnet, EBSCO Host and Scopus was performed using the descriptors Coronavirus Infections, COVID-19, Drug therapy, and pharmacological treatment. The selection criteria were quantitative research articles of any type of design, in English and Spanish, available in full text, obtaining a sample of 24 articles.  Results Most of the studies were integrative reviews with a percentage of 66.6 and clinical or in vitro trials with a percentage of 12.5. Nine drugs of major use in COVID-19 were identified in the drug therapy, that is, Hydroxychloroquine/Chloroquine, Lopinavir/Ritonavir, Remdesivir, Azithromycin, Ivermectin, Tocilizumab and Dexamethasone. However, According to the scientific evidence only four drugs showed significant effectiveness.  Conclusions Remdesivir demonstrated greater effectiveness and safety during the treatment, and Tocilizumab and Dexamethasone showed favorable results. Nevertheless, the results are not conclusive. The authors pointed out that so far is not possible to conclude there are treatments that effectively fight COVID-19.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[Infecciones por coronavirus]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento farmacológico (DeCS, MeSH)]]></kwd>
<kwd lng="pt"><![CDATA[COVID-19]]></kwd>
<kwd lng="pt"><![CDATA[Infecções por Coronavírus]]></kwd>
<kwd lng="pt"><![CDATA[Tratamento Farmacológico (DeCS)]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[Coronavirus Infections]]></kwd>
<kwd lng="en"><![CDATA[Pharmacological Treatment (DeCS, MeSH)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Organización para la Cooperación y el Desarrollo Económico</collab>
<source><![CDATA[Health at a Glance: Latin America and the Caribbean 2020]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Paris ]]></publisher-loc>
<publisher-name><![CDATA[OECD Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Aceleración de la propagación de la COVID-19]]></source>
<year></year>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Statement on the fifth meeting of the International Health Regulations, 2005. Emergency Committee regarding the coronavirus disease (COVID-19) pandemic]]></source>
<year>2005</year>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shankar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dubey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ch.]]></surname>
<given-names><![CDATA[Prakash]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of complementary an alternative medicine in prevention and treatment of COVID-19: An overhyped hope]]></article-title>
<source><![CDATA[Chin J Integr Med]]></source>
<year>2020</year>
<volume>26</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>565-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crespillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abordaje terapéutico en pacientes con infección por coronavirus SAR-COV-2]]></article-title>
<source><![CDATA[Act. Farm Terap]]></source>
<year>2020</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helmy]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fawzy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elaswad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sobieh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kenney]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shehata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The COVID-19 Pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment and control]]></article-title>
<source><![CDATA[J. Clin. Med]]></source>
<year>2020</year>
<volume>9</volume>
<numero>1225</numero>
<issue>1225</issue>
<page-range>1-29</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ouanounou]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19: A review of the proposed pharmacological treatments]]></article-title>
<source><![CDATA[Eur J of Pharmacol]]></source>
<year>2020</year>
<volume>886</volume>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Manejo clínico de la COVID-19. Orientaciones provisionales]]></source>
<year>2019</year>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santillán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en el tratamiento de COVID-19]]></article-title>
<source><![CDATA[Archivos Venezolanos de Farmacología y Terapéutica]]></source>
<year>2020</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 -2 infection in vitro]]></article-title>
<source><![CDATA[Cell Discov]]></source>
<year>2020</year>
<volume>6</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gautret]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lagier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parola]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hoang]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Meddeb]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mailhe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial, Francia]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2020</year>
<volume>56</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poschet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Perkett]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Timmins]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Deretic]]></surname>
<given-names><![CDATA[Vojo]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells]]></article-title>
<source><![CDATA[Preprints from mesdRxiv and bioRxiv]]></source>
<year>2020</year>
<volume>3</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>1-21</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caly]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Druce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Catton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jans]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wagstaff]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The FDA approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro]]></article-title>
<source><![CDATA[Antiviral Res]]></source>
<year>2020</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>787</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choudhary]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[AK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential Use of Hydroxychloroquine, Ivermectin, and Azithromycin Drugs in the Fight Against COVID-19: Trends, Scope, and Relevance]]></article-title>
<source><![CDATA[New Microbes and New Infect]]></source>
<year>2020</year>
<volume>1</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Tratamientos disponibles sujetos a condiciones especiales de acceso para el manejo de la infección respiratoria por SARS CoV-2]]></source>
<year>2020</year>
<publisher-name><![CDATA[España]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wayah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Auta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Waziri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Haruna]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insights on potential therapeutic options and vaccines for coronavirus disease-2019]]></article-title>
<source><![CDATA[Reviews in Medical Microbiology]]></source>
<year>2020</year>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benavides]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Reposicionamiento de medicamentos para COVID - 19]]></source>
<year>2020</year>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-11</page-range><publisher-loc><![CDATA[Colomb Med (Cali) ]]></publisher-loc>
<publisher-name><![CDATA[Universidad del Valle, Facultad de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grove]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<source><![CDATA[Investigación en enfermería. Desarrollo de la práctica enfermera basada en la evidencia]]></source>
<year>2019</year>
<edition>7</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guevara-Valtier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cárdenas-Villarreal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Cortes]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Protocolos de investigación en Enfermería]]></source>
<year>2017</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Manual Moderno]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<collab>Descriptores en Ciencias de la Salud</collab>
<source><![CDATA[Biblioteca Virtual en Salud]]></source>
<year>2021</year>
<publisher-name><![CDATA[Organización Panamericana de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Medical Subject Heading</collab>
<source><![CDATA[]]></source>
<year>2021</year>
<publisher-name><![CDATA[National Library of Medecine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 Drug Treatment in China]]></article-title>
<source><![CDATA[Curr Pharmacol Reports]]></source>
<year>2020</year>
<volume>6</volume>
<page-range>146-54</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tzu-Han]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chian-Ying]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yi-Fan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chian-Shiu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aliaksandr]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Tzu-Ying]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review and meta-analysis of the effectiveness and safety of hidroxychloroquine in treating Covid-19 patients]]></article-title>
<source><![CDATA[J Chin Med Assoc]]></source>
<year>2020</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-31</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tlayjeh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mhish]]></surname>
<given-names><![CDATA[OH]]></given-names>
</name>
<name>
<surname><![CDATA[Enani]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Alruwaili]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tleyjeh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Thalib]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of corticosteroid use and outcomes in COVID-19 patients: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Infect Public Heal]]></source>
<year>2020</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1652-63</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicines for the treatment of COVID-19: Awaiting the evidence]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2020</year>
<volume>33</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>500-4</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reina]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remdesivir, la esperanza antiviral frente al SARS-CoV-2]]></article-title>
<source><![CDATA[Rev. Esp. Quimioter]]></source>
<year>2020</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>176-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Amezaga- Menéndez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal-Cortés]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Escapa]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Subeviola]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano-Lázaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento farmacológico de la COVID-19: revisión narrativa de los grupos de trabajo de enfermedades infecciosas y sepsis (GTEIS) y del grupo de trabajo de transfusiones hemoderivados (GTTH)]]></article-title>
<source><![CDATA[Med. Intensiva]]></source>
<year>2020</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>104-21</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzales-Zamora]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento exitoso con remdesivir y corticoides en un paciente con neumonía asociada a COVID-19: reporte de un caso]]></article-title>
<source><![CDATA[Medwave]]></source>
<year>2020</year>
<volume>20</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<collab>Organización Panamericana de la Salud</collab>
<source><![CDATA[Recomendación sobre uso de ivermectina en el tratamiento de COVID-19]]></source>
<year>2020</year>
<publisher-name><![CDATA[OPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[Liu]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ruan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<page-range>1787-99</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Monogue]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Jodlowski]]></surname>
<given-names><![CDATA[TZ]]></given-names>
</name>
<name>
<surname><![CDATA[Cutrell]]></surname>
<given-names><![CDATA[JB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>323</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1824-36</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Dufort]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Udo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wilberschied]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tesoriero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>323</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2493-502</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spinner]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Gottlieb]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Criner]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Arribas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Cattelan]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>324</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1048-57</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jimbo-Sotomayor]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Jaramillo]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Piedrahita]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Ivermectina para el tratamiento de la infección COVID-19]]></source>
<year>2020</year>
<publisher-name><![CDATA[Pontificia Universidad Católica del Ecuador]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huamán-Sánchez]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Efectividad y seguridad tocilizumab en el tratamiento de COVID-19]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Perú ]]></publisher-loc>
<publisher-name><![CDATA[Unidad de Análisis y Generación de Evidencias en Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pareja]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Luque]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alternativas terapéuticas farmacológicas para COVID-19]]></article-title>
<source><![CDATA[Horiz. Med]]></source>
<year>2020</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moneriz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Salguedo]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fármacos prometedores y potenciales para el tratamiento de COVID-19]]></article-title>
<source><![CDATA[Revista Chilena de Infectología]]></source>
<year>2020</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>205-15</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Tejeda]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dieguez-Guach]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Abreu]]></surname>
<given-names><![CDATA[MR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alternativas terapéuticas para el manejo de COVID - 19]]></article-title>
<source><![CDATA[Rev Habanera Cienc.]]></source>
<year>2020</year>
<volume>19</volume>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos-Sánchez]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Salas-Coronado]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Origen, características estructurales, medidas de prevención, diagnóstico y fármacos potenciales para prevenir y controlar COVID-19]]></article-title>
<source><![CDATA[Med Wave]]></source>
<year>2020</year>
<volume>20</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1-28</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Youn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Noh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cheong]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study]]></article-title>
<source><![CDATA[J. Glob. Infect. Dis]]></source>
<year>2020</year>
<volume>102</volume>
<page-range>275-81</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheahan]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Sims]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Leist]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Schäfer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Won]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV]]></article-title>
<source><![CDATA[Nat. Commun]]></source>
<year>2020</year>
<volume>11</volume>
<numero>222</numero>
<issue>222</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="book">
<collab>Secretaría de Salud</collab>
<source><![CDATA[Propuesta de medicamentos para el tratamiento de COVID-19. Subsecretaría de Integración y Desarrollo del Sector Salud]]></source>
<year>2020</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Dirección General de Planeación y Desarrollo en Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cepelowicz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fatteh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rajter]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ICON Study]]></article-title>
<source><![CDATA[Chest Infections]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
